We are dedicated to developing meaningful treatment options for those with skeletal dysplasias

Infigratinib is the first ever investigational therapy for achondroplasia to be awarded breakthrough therapy designation by the FDA.

Now enrolling in ACCEL, an observational study for our hypochondroplasia program.